Olaratumab (IMC-3G3)

Biologic Inhibitors of KIT and PDGFRA

In contrast to the small-molecule drugs taken orally known as tyrosine kinase inhibitors (such as imatinib and sunitinib), biologic inhibitors work by different mechanisms.  Whereas tyrosine kinase inhibitors bind to portions of the KIT or PDGFRA receptor inside the cell membrane, monoclonal antibodies recognize the portions of the receptors that protrude outside the cell membrane and bind to these.  Another type of biologic inhibitor that could be developed in the future would interfere with RNA, thereby preventing the production of the undesired receptor proteins.

Olaratumab (IMC-3G3)